Applicants: David Stern, et al.

Serial No.: 10/049,893 Filed: July 22, 2002

Page 2

is being timely filed.

## Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

## 1-41. (Canceled)

42. (Currently Amended) A method for preventing and/or treating a disease involving  $\beta$ -sheet fibril formation, other than Alzheimer's Disease, in a subject which comprises administering to the subject a bindinginhibiting amount of a compound other than sRAGE, which compound (i) comprises a fragment of sRACE and (ii) is capable of inhibiting binding of the β-sheet fibril to RACE an amount of a soluble compound which comprises a V-domain of RAGE effective to inhibit binding of the  $\beta$ -sheet fibril to receptor for advanced glycation endproduct, wherein the  $\beta$ -sheet fibril is formed from an amyloid-β peptide selected from the group consisting of  $\Lambda\beta$  (1-39),  $\Lambda\beta$  (1-40),  $\Lambda\beta$  (1-42) and Aβ (1-40) Dutch variant comprises amylin, amyloid A, transthyretin, cystatin C, or gelsolin, so as to thereby prevent and/or treat a the disease involving formation other than Alzheimer's fibril Disease in the subject.

## 43-58. (Canceled)

59. (Previously Presented) The method of claim 42, wherein

Applicants: David Stern, et al.

Serial No.: 10/049,893 Filed: July 22, 2002

Page 3

the subject is a mammal.

- 60. (Previously Presented) The method of claim 59, wherein the mammal is a human being.
- 61. (Previously Presented) The method of claim 59, wherein the administration is intralesional, intraperitoneal, intramuscular, intravenous, liposome mediated delivery, topical, nasal, oral, anal, ocular or otic delivery.

## 62-69. (Canceled)

- 70. (Previously Presented) The method of claim 42, wherein the  $\beta$ -sheet fibril comprises a peptide capable of forming amyloid.
- 71. (New) The method of claim 42, wherein the soluble compound comprises the V-domain of RAGE linked to an antibody or a portion of an antibody.
- 72. (New) The method of claim 42, wherein the soluble compound comprises the V-domain of RAGE linked to a portion of an antibody.
- 73. (New) The method of claim 42, wherein the portion of the antibody is a  $F_{ab}$  fragment.
- 74. (New) The method of claim 42, wherein the portion of the antibody is an  $F_c$  fragment.

Applicants: David Stern, et al.

Serial No.: 10/049,893 Filed: July 22, 2002

Page 4

- 75. (New) The method of claim 42, wherein the  $\beta$ -sheet fibril comprises amylin.
- 76. (New) The method of claim 42, wherein the  $\beta$ -sheet fibril comprises amyloid A.
- 77. (New) The method of claim 42, wherein the  $\beta$ -sheet fibril comprises transthyretin.
- 78. (New) The method of claim 42, wherein the  $\beta$ -sheet fibril comprises cystatin C.
- 79. (New) The method of claim 42, wherein the  $\beta\text{-sheet}$  fibril comprises gelsolin.